High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial.
J Child Neurol
; 23(11): 1300-4, 2008 Nov.
Article
in En
| MEDLINE
| ID: mdl-18984840
This is the first study to evaluate the efficacy of riboflavin for migraine prophylaxis in children. This was a randomized, double-blind study of riboflavin (200 mg daily) versus placebo in 48 children. The primary efficacy measure was the number of patients achieving a 50% or greater reduction in the number of migraine attacks per 4 weeks. Other outcome measures were the mean severity of migraine per day, mean duration of migraine, days with nausea or vomiting, analgesic use, and adverse effects. A 50% or greater reduction in headaches was seen in 14/21 patients in the placebo group and 12/27 patients in the riboflavin group (not significant P = .125). There were no differences between riboflavin and placebo for primary or secondary outcome variables. These results suggest that riboflavin is not an effective therapy for preventing migraine in children. A high placebo responder rate was seen, with implications for other studies of migraine in children.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Riboflavin
/
Vitamin B Complex
/
Migraine Disorders
Type of study:
Observational_studies
Limits:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Language:
En
Journal:
J Child Neurol
Journal subject:
NEUROLOGIA
/
PEDIATRIA
Year:
2008
Document type:
Article
Affiliation country:
Country of publication: